2.58
+0.03(+1.18%)
Currency In USD
| Previous Close | 2.55 |
| Open | 2.74 |
| Day High | 2.74 |
| Day Low | 2.55 |
| 52-Week High | 9.2 |
| 52-Week Low | 2.55 |
| Volume | 54,121 |
| Average Volume | 55,229 |
| Market Cap | 22.96M |
| PE | -0.46 |
| EPS | -5.67 |
| Moving Average 50 Days | 3.52 |
| Moving Average 200 Days | 4.64 |
| Change | 0.03 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $13.23 as of May 09, 2025 at a share price of $2.58. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $12.1 as of May 09, 2025 at a share price of $2.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Newsfile
May 07, 2025 12:00 PM GMT
Salt Lake City, Utah--(Newsfile Corp. - May 7, 2025) - Clene Inc. (NASDAQ: CLNN), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Rob Etherington, P
Clene to Present at the Emerging Growth Conference
GlobeNewswire Inc.
Apr 14, 2025 12:30 PM GMT
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY-MSOver 90% of participants who